Acumen Physician Solutions

  • Products
    • Acumen Epic Connect
    • Acumen Nephrologixx
  • Blog
  • Connect
    • Acumen Community
    • Events
  • About Us
    • Our Customers
    • Leadership Team
    • Careers
  • Contact Us
  • (877) 535-5566
  • Login
    • Acumen Dialysis &
      Hospital Rounding
    • Acumen Epic Connect

Transitioning from Part D to Part B: A Medicare Story

Acumen Staff
October 30, 2017 Leave a Comment

Following the U.S. Food and Drug Administration’s recent approval of Parsabiv™ (etelcalcetide), an IV formulation equivalent to the oral calcimimetic Sensipar® (cinacalcet), dialysis providers like Fresenius Kidney Care have been diligently preparing for a new fulfillment process for Sensipar. Under the Medicare End Stage Renal Disease (ESRD) prospective payment system (the “Bundle”), when an IV formulation of an oral-only drug used for the treatment of ESRD becomes available, both formulations become reimbursable under Medicare Part B. The reclassification of Sensipar by the Centers for Medicare and Medicaid (CMS) under the ESRD payment system is effective January 1, 2018. CMS will evaluate the utilization of both formulations during a two-year transition period then adjust the base rate of the Bundle accordingly.

While patients are accustomed to the traditional prescription fulfillment process under Medicare Part D whereby a physician provides a patient with a prescription to be fulfilled at the pharmacy of the patient’s choice, patients may not be as familiar with the Part B process. For patients with Medicare Part B primary benefits, their dialysis provider will be responsible for providing Sensipar via a pharmacy of the provider’s choice after January 1.

To ensure compliance with therapy and to better support our patients, Fresenius Kidney Care has chosen FreseniusRx to provide Sensipar to its Medicare Part B patients after January 1. FreseniusRx pharmacists are trained in renal disease and specialize in renal medication. The transition of Sensipar from Part D to Part B provides FMCNA an opportunity to further integrate pharmacists into the care of our patients under a value-based care model.

Navigating a new fulfillment process for the drug may cause some patients confusion. You can help your patients by ensuring they understand the change in how Part B medications are provided and paid for and why CMS bundles certain medication with treatment for better integrated care.

Jeffrey L. Hymes, M.D., is Chief Medical Officer and Senior Vice President of Fresenius Kidney Care and Chairman of the Pharmacy and Therapeutics Committee. Dr. Hymes served as President of Nephrology Associates in Nashville, TN, and as President and CMO of National Nephrology Associates. He is a former member of the Renal Physicians Association Board of Directors, and is board certified in Internal medicine, Nephrology and Critical Care.

Related Posts

  • Intravenous Form of Sensipar<sup>®</sup> Has Been Approved by the FDAIntravenous Form of Sensipar® Has Been Approved by the FDA
  • Nephrology News RoundupNephrology News Roundup
  • Dialysis 5-Star Rating: The Curse of the Bell CurveDialysis 5-Star Rating: The Curse of the Bell Curve

Filed Under: Blog, Sensipar Tagged With: Bundle, CMS, ESRD, FMCNA, Fresenius Kidney Care, FreseniusRx, Jeffrey L. Hymes, Medicare Part B, Medicare Part D, Parsabiv, Sensipar

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Recent Posts

  • Interwell Health Celebrates 5M Patient Charts in Acumen Epic Connect
  • Acumen Achieves 2023 Epic Connect Accreditation!
  • The CMS Quality Payment Program: Future Impact on the Medicare Physician Fee Schedule
  • Raising the Bar: ETC Updates for 2022 Are In!
  • Telehealth: Current State/Future State

Blog Categories

Subscribe to our Blog

Acumen Community

Corporate Headquarters
1000 Corporate Centre Drive, Suite 400
Franklin, TN 37067

(615) 567-4700
(877) 535-5566 Toll Free
(615) 567-4705 Fax

Search this site

Acumen Physician Solutions is an InterWell Health company.

  • Facebook
  • LinkedIn
  • Twitter
Copyright © Acumen Physician Solutions  •  User Agreement and Privacy Policy